论文部分内容阅读
目的分析EGFR基因与非小细胞肺癌疗效的相关性研究。方法选取2014年2月至2016年5月期间我院收治已确诊的非小细胞肺癌100例患者为研究对象,运用ADx-ARMSEGFR基因突变检测试剂,并对100例未给予过Gefitinib治疗的非小细胞肺癌患者进行检测,分析EGFR基因外显子18,19,20以及21突变的情况。结果非小细胞肺癌患者的总EGFR基因突变率为49%;EGFR基因突变在肺鳞状细胞癌的突变率显著低于肺腺癌组织中的基因突变率(P<0.05),且EGFR基因在男性患者突变率为显著低于在女性患者突变率(P<0.05)。结论我国非小细胞肺癌中特别是肺腺癌患者存在较高的EGFR基因突变率,将患者的的临床病理特征与EGFR基因突变中的外显子21和外显子19突变结合能够成为评价TKI治疗非小细胞肺癌患者的重要标志之一。
Objective To analyze the correlation between the EGFR gene and the efficacy of non-small cell lung cancer. Methods From February 2014 to May 2016, 100 patients with confirmed non-small cell lung cancer admitted to our hospital were selected as research objects. ADX-ARMSEGFR gene mutation detection reagent was selected and 100 non-small-size non-small-cell lung cancer patients Cell lung cancer patients were tested for EGFR gene exons 18,19,20 and 21 mutations. Results The overall mutation rate of EGFR gene in non-small cell lung cancer was 49%. The mutation rate of EGFR gene in lung squamous cell carcinoma was significantly lower than that in lung adenocarcinoma (P <0.05) The mutation rate was significantly lower in male patients than in female patients (P <0.05). Conclusion There is a high EGFR gene mutation rate in NSCLC, especially in patients with lung adenocarcinoma. Combining the clinicopathological features of the patients with the mutations of exon 21 and exon 19 in EGFR gene mutation can be used to evaluate the TKI Treatment of non-small cell lung cancer in patients with one of the important signs.